Randomised Double Blinded Placebo Controlled Trial of Magnesium Sulphate in Reducing Length of Hospital Stay In Patients Undergoing Elective Large Bowel Resection

| Submission date | Recruitment status | Prospectively registered |
|-------------------|----------------------|--|
| 03/12/2004 | Stopped | ☐ Protocol |
| Registration date | Overall study status | Statistical analysis plan |
| 21/02/2005 | Stopped | Results |
| Last Edited | Condition category | Individual participant data |
| 16/06/2011 | Digestive System | Record updated in last year |

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr James Pitt

Contact details

Department of Surgery
Ipswich Hospital NHS Trust
Heath Road
Ipswich
United Kingdom
IP4 5PD
+44 (0)1473 703755
james.pitt@ipswichhospital.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

04/Q0102/39

Study information

Scientific Title

Acronym

Magnesium Trial

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Large bowel resection

Interventions

Trial never started.

This study aimed to involve patients undergoing elective large bowel resection (right and left hemicolectomy, sigmoid colectomy and anterior resection) at the Ipswich Hospital for benign or malignant disease of the colon and rectum.

Patients were to have been randomised to receive either oral magnesium sulphate (1 g oral suspension, twice daily) or a placebo (oral suspension, twice daily) for 5 days. The status of the subjects, whether those taking the active substance or the group taking the placebo drug would

not be known by the investigators as this was to be a double blinded study. The pharmacy would produce the inactive placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Magnesium sulphate

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

02/01/2005

Completion date

30/06/2006

Reason abandoned (if study stopped)

Never started.

Eligibility

Key inclusion criteria

We intend to recruit 108 subjects initially as follows:

A sample size of 54 in each group will have 90% power to detect a probability of 0.319* that an observation in Group 1 is less than an observation in Group 2 using a Wilcoxon (Mann-Whitney) rank-sum test with a 0.050 two-sided significance level.

*From a mean length of stay of 6 days in one group (Group 1) and 8 in the other group (Group 2), with a Standard Deviation of 3.000.

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

108

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

02/01/2005

Date of final enrolment

30/06/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Department of Surgery

Ipswich United Kingdom IP4 5PD

Sponsor information

Organisation

Ipswich Hospital NHS Trust (UK)

Sponsor details

Heath Road
Ipswich
England
United Kingdom
IP4 5PD
+44 (0)1473 704343
research.office@ipswichhospital.nhs.uk

Sponsor type

Hospital/treatment centre

Funder(s)

Funder type

Government

Funder Name

Ipswich Hospital NHS Trust (UK)

Results and Publications

Publication and dissemination planNot provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration